Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angiotensin II versus placebo during lung transplantation
ACTRN12625001374459Phase 3Not yet recruiting
- Sponsor
- Alfred Health
- Start
- Feb 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute kidney failure (AKF) comparing Angiotensin II infusion with Placebo infusion (2 arms). Primary endpoints: Feasibility - drug dose delivered in 48 hours, Compliance rate and 1 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
Angiotensin II
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on ACTRN12625001374459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001374459.